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Background: TRK fusion cancer results from gene fusions involving NTRK1, NTRK2
or NTRK3. Larotrectinib, the first selective TRK inhibitor, has demonstrated an overall
response rate (ORR) of 75% with a favorable safety profile in the first 55 consecutively
enrolled adult and pediatric patients with TRK fusion cancer (Drilon et al.,NEJM2018).
Here, we report the clinical activity of larotrectinib in an additional 35 TRK fusion can-
cer patients and provide updated follow-up of the primary analysis set (PAS) of 55
patients as of 19thFeb 2018.
Methods: Patients with TRK fusion cancer detected by molecular profiling from 3 laro-
trectinib clinical trials (NCT02122913, NCT02637687, and NCT02576431) were
eligible.Larotrectinib was administered until disease progression, withdrawal, or unac-
ceptable toxicity. Disease status was assessed using RECIST version 1.1.
Results: As of Feb 2018, by independent review, 6 PRs in the PAS deepened to CRs. The
median duration of response (DoR) and progression-free survival in the PAS had still
not been reached, with 12.9 months median follow-up. At 1 year, 69% of responses
were ongoing, 58% of patients remained progression-free and 90% of patients were
alive. An additional 19 children and 25 adults (age range, 0.1-78 years) with TRK fusion
cancer were enrolled after the PAS, and included cancers of the salivary gland, thyroid,
lung, colon, melanoma, sarcoma, GIST and congenital mesoblastic nephroma. In 35
evaluable patients, the ORR by investigator assessment was 74% (5 CR, 21 PR, 6 SD, 2
PD, 1 not determined). In these patients, with median follow-up of 5.5 months, median
DoR had not yet been reached, and 88% of responses were ongoing at 6 months, consis-
tent with the PAS. Adverse events (AEs) were predominantly grade 1, with dizziness,
increased AST/ALT, fatigue, nausea and constipation the most common AEs reported
in 10% of patients. No AE of grade 3 or 4 related to larotrectinib occurred in more
than 5% of patients.
Conclusions: TRK fusions are detected in a broad range of tumor types. Larotrectinib
is an effective age- and tumor-agnostic treatment for TRK fusion cancer with a positive
safety profile. Screening patients for NTRK gene fusions in solid- and brain tumors
should be actively considered.
Clinical trial identification: NCT02122913, NCT02637687, and NCT02576431.
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